(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
Common Stock, par value $0.001 per share
VTGN
Nasdaq Capital Market
On February 1, 2021, Mark J. Ginski, Ph.D. joined VistaGen Therapeutics, Inc. (the "Company" or "VistaGen") as Senior Vice President, Head of CMC (Chemistry, Manufacturing and Controls).
Dr. Ginski, age 49, joined VistaGen with over 25 years of broad CMC leadership experience, spanning preclinical and clinical development through commercial manufacturing of both drug substance and drug product for small molecules, peptides and biologics. Since September 2020, Dr. Ginski has been acting as a part-time consultant to the Company, providing certain CMC advisory services to the Company. Prior to September 2020, Dr. Ginski served as Vice President, Product Development for ANI Pharmaceuticals from May 2016 to June 2020. From July 2013 to May 2016, Dr. Ginski served as Senior Director, CMC and Operations, Autoimmune and Rare Diseases for Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals. Dr. Ginski has previously held various leadership positions with Guilford Pharmaceuticals, Shire Pharmaceuticals and Alba Therapeutics. Dr. Ginski holds a B.S. in Biological Sciences from the University of Maryland and received his Ph.D. in Pharmaceutical Studies from the University of Maryland School of Pharmacy.
There are no arrangements or understandings between Dr. Ginski and any other person pursuant to which he joined the Company, and Dr. Ginski is not a participant in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.
VistaGen Therapeutics, Inc. |
By: | /s/ Shawn K. Singh |
Name: Shawn K. Singh | |
Title: Chief Executive Officer |